Global Genomic Testing Market By Type (Primary Erythromelalgia, Secondary Erythromelalgia), By Treatment (Drug, Surgery), By Route of Administration (Oral, Topical), By End-User (Hospitals, Homecare Settings, Specialty Clinics, Other End-Users), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031
- Published date: March 2023
- Report ID: 73831
- Number of Pages: 277
- Format:
- keyboard_arrow_up
Erythromelalgia (EM) is a rare condition that affects the feet and sometimes the hands. It is known to cause intense burning pain, severe redness, and an increase in skin temperature that can be episodic or continuous. Swelling, soreness, a deep painful aching of soft tissue, and intense burning sensations are the most common symptoms of EM. The feet are generally more affected, but symptoms can also impact the hands, face, and eyes.
EM has been classified as either primary or secondary. Primary EM relates to certain genes or is idiopathic, which means it has no recognized cause. This type of EM is more common in youngsters, particularly in their first ten years of life, but it can affect anyone at any age. Symptoms in some young individuals may begin throughout puberty.
Secondary EM is associated with other diseases or conditions, especially autoimmune diseases and myeloproliferative disorders (diseases of the blood and bone marrow). Adults are more likely to develop it, with the onset generally occurring during middle-age.
There is no one-size-fits-all treatment or cure for EM. Treating the underlying issue in secondary EM may provide relief. EM is rarely totally treatable. Doctors will focus on symptom treatment in these cases. Non-pharmacological methods should be used first, followed by topical medications, oral medications, pain rehabilitation programs, and in extreme circumstances surgery. Finding a treatment strategy that works may take some time. Surgery is considered when no other treatments provide relief.
Detailed Segmentation
The global erythromelalgia treatment market is segmented on the basis of – Type, Treatment, Route of Administration, End-User, and Region.
Based on Type
- Primary Erythromelalgia
- Secondary Erythromelalgia
Based on Treatment
- Drug
- Surgery
Based on Route of Administration
- Oral
- Topical
Based on End-User
- Hospitals
- Homecare Settings
- Specialty Clinics
- Other End-Users
Based on Regions
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Market Dynamics
One of the primary factors influencing the revenue growth of the erythromelalgia treatment market is the increase in the number of people suffering from this disease around the world. The high need for medications such as lidocaine, capsaicin, diclofenac, brimonidine, misoprostol, etc., to treat rare diseases, as well as the high demand for disease-specific innovative treatments for patients, are propelling this industry forward. This market is also influenced by financial support from respective governments to increase research efforts to create novel interventions, as well as to increase the number of mergers among key industry players.
Additionally, improvements in healthcare infrastructures, increased investments, and a greater focus on rare disorders all benefit this market for erythromelalgia treatments. Furthermore, the increased need for disease-specific new treatments would provide profitable prospects for market players.
However, the high costs of treating and diagnosing parenteral nutrition-associated cholestasis is projected to hinder market expansion opportunities. A lack of qualified expertise is also expected to pose a challenge to the erythromelalgia therapy market over the forecast period.
Key Players:
- Teva Pharmaceutical Industries Ltd.
- Biogen Inc.
- Pfizer Inc.
- Akorn Inc.
- Novartis A.G.
- Galderma S.A.
- Acorda Therapeutics Inc.
- AbbVie Pharmaceuticals
- Bausch Health Companies Inc.
- Other Key Players
For the Erythromelalgia Treatment Market research study, the following years have been considered to estimate the market size:
Particular Scope Region - North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Historic Year 2016 to 2020 Base Year 2021 Estimated Year 2022 Forecast Year 2023 to 2032 Erythromelalgia Treatment MarketPublished date: March 2023add_shopping_cartBuy Now get_appDownload Sample - Teva Pharmaceutical Industries Ltd. Company Profile
- Biogen Inc.
- Pfizer Inc Company Profile
- Akorn Inc.
- Novartis A.G.
- Galderma S.A.
- Acorda Therapeutics Inc.
- AbbVie Pharmaceuticals
- Bausch Health Companies Inc.
- Other Key Players
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |